7Suppliers
12Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Century Therapeutics, Inc. (IPSC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships
2Distinct source URLs
9High confidence
0.779Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Century Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
FCDI FCDI 92% On March 23, 2021, we entered into a Manufacturing and Supply Agreement with FCDI, or, as amended, the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology tran…
FUJIFILM-CELLULAR-DYNAMICS-INC FUJIFILM-CELLULAR-DYNAMICS-INC 92% FCDI provides certain services to the Company to develop and manufacture iPSCs and immune cells derived therefrom
ARTV Artiva Biotherapeutics, Inc. 72% Reciprocal relationship from ARTV graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and pro…
CELU Celularity Inc. 72% Reciprocal relationship from CELU graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the pla…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purpos…
GDTC CytoMed Therapeutics Limited 72% Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the…
INAB IN8bio, Inc. 72% Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…

Century Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
BMY Bristol-Myers Squibb Company 90% Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY grap…
BMY Bristol-Myers Squibb Company 90% the sublicenses under the FCDI Agreements pursuant to our former Research Collaboration and License Agreement with Bristol-Myers Squibb dated January 7, 2022, or the Collaboration Agreement
FCDI FCDI 90% Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, we paid to FCDI (i) an upfront payment of $10.0 million, and will pay (ii) a percentage of any milestone payme…
BMYMP Bristol-Myers Squibb Co 72% milestone payments upon the achievement of certain development and regulatory milestones up to an aggregate of $16.2 million or $12.15 million depending on the product. We additionally agreed to pay …
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMYM…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE g…
GDTC CytoMed Therapeutics Limited 72% Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any n…
INAB IN8bio, Inc. 72% Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…
TCRX TScan Therapeutics, Inc. 72% Reciprocal relationship from TCRX graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from TCRX g…
COMPANY-LLC COMPANY-LLC 62% or iPSC-derived allogeneic, cell therapy platforms; ● advance CNTY-813 and CNTY-308 through IND-enabling studies, submit IND applications and, if cleared, initiate and conduct clinical trials; ● cont…
FUJIFILM-CELLULAR-DYNAMICS-INC FUJIFILM-CELLULAR-DYNAMICS-INC 62% hospital processes are just beginning to be familiar and comfortable with their use. As a result, the execution and speed of enrollment of clinical trials in these novel and competitive areas are dif…
RHEINCELL-THERAPEUTICS-GMBH RHEINCELL-THERAPEUTICS-GMBH 62% hospital processes are just beginning to be familiar and comfortable with their use. As a result, the execution and speed of enrollment of clinical trials in these novel and competitive areas are dif…

Century Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IPSC-DEBT-10343 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
IPSC-DEBT-10342 Warrants outstanding: 16112 90% xbrl warrant detail from xbrl 2021-12-31.
IPSC-DEBT Debt stack $3.7M 90% Market cache reports total debt of $3.7M.

Century Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Century Therapeutics, Inc..

Century Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
IPSC-OWNER-RA-CAPITAL-MANAGEMENT-L-P RA CAPITAL MANAGEMENT, L.P. 90% 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 75 tracked holders.

Century Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CRSP CRISPR Therapeutics AG 100.00 2
ARTV Artiva Biotherapeutics, Inc. 100.00 1 ['supplier']
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
TLSA Tiziana Life Sciences Ltd 100.00 2
ACET Adicet Bio, Inc. 100.00 2
CRBU Caribou Biosciences, Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 2
AUTL Autolus Therapeutics plc 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
ATRA Atara Biotherapeutics, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
FATE Fate Therapeutics, Inc. 100.00 2 ['customer', 'supplier']
SDGR Schrödinger, Inc. 100.00 2
CLLS Cellectis S.A. 100.00 2
🔐
IPSC
Unlock IPSC Supply Chain Data
Verified relationships include:
FCDIFCDISupplier92%
FUJIFILM-CELLULAR-DYNAMICS-INCFUJIFILM-CELLULAR-DYNAMICS-INCSupplier92%
BMYBristol-Myers Squibb CompanyCustomer90%
BMYBristol-Myers Squibb CompanyCustomer90%
+19 more relationships locked
Subscribe — View plans →